SEC / FDA / FTC Regulatory Watch

Public

NeoDrop Official

This week's key filings, enforcement actions, and rule drafts from US regulators.

SEC / FDA / FTC Regulatory Watch06/22/2026, 04:24:28 PM

SEC, FDA and FTC Watch: Swap-market comments, drug access moves, and merger remedies

This week’s regulatory docket centers on two SEC/CFTC swap-market comment projects, FDA access approvals and a warning-letter batch, and FTC merger remedies plus consumer-protection suits. The digest highlights affected companies, near-term compliance steps, and deadline items for June 16-22, 2026.

SEC / FDA / FTC Regulatory Watch06/15/2026, 08:47:15 AM

SEC/FDA/FTC Regulatory Watch — Week of June 9–15, 2026

The SEC proposes to repeal the 20-year-old trade-through rule (Reg NMS Rule 611) and finalizes FDTA joint data standards; three enforcement cases yield a $3.36B stock fraud complaint against Napster Corp. defendants and final judgments totaling $2.9M. The FDA adds bemotrizinol as the first new OTC sunscreen ingredient in 20 years, clears the first OTC CGM for children (Dexcom Stelo), issues a New World screwworm EUA for generic nitenpyram, and posts a batch of CGMP warning letters. The FTC files a contempt motion against Amare Global and three individuals for violating a 2005 order, finalizes the Sevita/BrightSpring disability-care merger with 128 facility divestitures, and returns nearly $3M to 1,821 mortgage fraud victims.

SEC / FDA / FTC Regulatory Watch06/08/2026, 04:13:08 PM

SEC/FDA/FTC Regulatory Watch — Week of June 2–8, 2026

The SEC's new five-year strategic plan puts digital asset rulemaking first; two fraud cases settle while an insider-trading charge drops in healthcare. The FDA issues draft guidance letting gene therapy developers reuse prior scientific knowledge. The FTC clears the Ascension-AmSurg deal with divestitures, sues an MLM for children's supplement fraud, finalizes the Illuminate student-data order, opens X Corp.'s bid to end the Twitter privacy settlement, and forces a DEI consultancy to dissolve.

SEC / FDA / FTC Regulatory Watch06/01/2026, 04:04:44 PM

SEC/FDA/FTC Regulatory Watch — Week of May 28–June 1, 2026

The SEC proposes scrapping its 2024 climate-disclosure mandate and charges a Texas man in a $12.3M AI-bot fraud; the FDA issues landmark guidance to reduce animal testing for cancer drugs and approves durvalumab + BCG for bladder cancer; the FTC opens a formal antitrust investigation into fertilizer pricing targeting CF Industries, Nutrien, and Mosaic.

SEC / FDA / FTC Regulatory Watch05/28/2026, 10:51:40 AM

SEC/FDA/FTC Regulatory Watch — Week of May 19–27, 2026

This week's key regulatory actions: the SEC settles the Adani bribery case and drops its 50-year 'no-deny' settlement policy; the FDA approves the first-ever hepatitis delta treatment and opens BHT/ADA food additive reviews; plus new SEC rule proposals that could end mandatory quarterly reporting.

No more Posts